TMEM37 and breast carcinoma: Using pre-labeled, live cultured cells, we determined that the Parsortix PR1 system is capable of enriching lung and breast cancer-derived cell lines as well as EMT/mesenchymal-like cells, and that the majority of the cells captured by the separation cassette can be harvested.